12.18.2018 Issue 432

Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Report: Federal Judge Rules
ACA Unconstitutional After Penalty Removed

Monday, December 17

A federal judge on Friday, Dec. 14, ruled that the Affordable Care Act, after Congress nixed a penalty for consumers who didn’t have insurance, is unconstitutional, The Wall Street Journal reports.

Article: Value-Based Pricing and Reimbursement Remains Mostly Promise

Dubois: Challenges Remain for Integrating Personalized Medicine, Value Frameworks

FDA Moves on Biosimilars, Outlines New Plans

Research Suggests Low-Cost Generics at High Risk of Shortages

Interest in Expanded Use of RWD Continues to Grow

Report: Pharma Price Hikes Fewer, Smaller at Beginning of 2018

ICER President Discusses Group’s Mission

Researcher - HEOR

Executive Director, Health Technology Assessment (HTA) Statistics (U.S.)

Executive Director, Health Technology Assessment (HTA) Statistics (U.K.)

Associate Director, Health Economics & Outcomes Research

Industry Spotlight

Conferences Webinars
Reimbursement and Contracting
    January 23-24, Philadelphia, Pennsylvania

Data Analytics and Decisions
    January 23-24, Philadelphia, Pennsylvania

Special Therapies 2019
    January 24-25, Las Vegas, Nevada

Identifying Medical Conditions in Administrative Claims Data: Validation and Machine Learning
    January 8

HEOR & RWE: Global Sourcing Strategies and Best Practices
    January 24

Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Paying for Digital Health: Payer Insights

Benchmarking Pharma’s MSL Capabilities

Charting Real World Data and Evidence – Activity and Capabilities (2018)

From Patent to Patient: Analyzing Access to Innovative Cancer Drugs

Transitioning Payment Models: Fee-for-Service to Value-Based Care

How Health Plans and Providers Can Collaborate to Improve Care Transitions and Reduce Hospital Readmissions

Generating Consensus and Trust for Quality Measurement to Support Value-Based Care

An Evidence-Based Approach to Hiring: Leaders, Physicians, Nurses, and Front Line Staff

Special Thanks to Our Partners:
               Evidera   HealthCore  
      University of FL   Xcenda  OM1    Parexel   Jefferson
      Dymaxium   Precision Xtract    Pharmerit    eMax Health
      Sciformix   Evidence Partners    ICON    Truven
Share this newsletter on social media:

Email Twitter Facebook LinkedIn